Clinical Trials Logo

Clinical Trial Summary

Anlotinib is a novel oral multitarget tyrosine kinase inhibitor and primary targeted to VEGFR, FGFR, PDGFR and c-Kit. This study intends to assess the efficacy and safety of anlotinib combined with platinum/gemcitabine for first line treatment of advanced urothelial carcinoma.

Clinical Trial Description

The primary objective is to determine the antitumor activity of anlotinib combined with platinum/gemcitabine (Objective Response rate, ORR) in patients with advanced urothelial carcinoma. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05030077
Study type Interventional
Source Tianjin Medical University Second Hospital
Contact Hailong Hu, MD,PhD
Phone 0086-13662096232
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date October 1, 2021
Completion date September 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Recruiting NCT02795156 - Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Phase 2
Active, not recruiting NCT03039413 - Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy Early Phase 1
Recruiting NCT03915405 - KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer Phase 1
Active, not recruiting NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Recruiting NCT04452214 - A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors Phase 1
Active, not recruiting NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Active, not recruiting NCT01093066 - Prospective Multicentric Evaluation of a Bladder Preservation Strategy Phase 2
Not yet recruiting NCT04879329 - A Study of RC48-ADC in Patients With HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Phase 2
Terminated NCT01042795 - Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy Phase 2
Recruiting NCT03212404 - Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Phase 1
Recruiting NCT04077359 - Prospective Trial for Examining Hematuria Using Computed Tomography N/A
Active, not recruiting NCT03272217 - Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer Phase 2
Recruiting NCT03988309 - The Cxbladder Hematuria Clinical Utility Study N/A
Recruiting NCT03606174 - Study of Sitravatinib + PD-(L)1 Checkpoint Inhibitor Regimens in Urothelial Carcinoma Phase 2
Active, not recruiting NCT01688999 - Cabozantinib for Advanced Urothelial Cancer Phase 2
Recruiting NCT05043662 - UroCAD Assay Combined With Computed Tomography Urography and Urine Cytology for UTUC Diagnosis.
Active, not recruiting NCT03133390 - Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients Phase 2